GO:0031392 regulation of prostaglandin biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031392 describes any process that modulates the frequency, rate, or extent of prostaglandin biosynthesis, a central lipid signaling pathway.
• Prostaglandin biosynthesis is controlled at multiple levels, including phospholipase A2-mediated arachidonic acid release, cyclooxygenase (COX) activity, and terminal prostaglandin synthases.
• Post-transcriptional regulation by microRNAs and AU-rich elements (AREs) tightly controls prostaglandin synthesis genes.
• Prostaglandin transport via SLCO2A1 and other transporters is a key regulatory node affecting local prostaglandin levels.
• Dysregulated prostaglandin biosynthesis contributes to inflammation, cancer, cardiovascular disease, and metabolic disorders.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting causal roles of genes regulating prostaglandin biosynthesis.
Description
Prostaglandins are lipid mediators derived from arachidonic acid that regulate diverse physiological processes including inflammation, vascular tone, and immune responses. The Gene Ontology term GO:0031392, regulation of prostaglandin biosynthetic process, encompasses any process that modulates the frequency, rate, or extent of the chemical reactions and pathways leading to prostaglandin formation. This term is critical for understanding how cells control the production of these potent signaling molecules under normal and pathological conditions. Prostaglandin biosynthesis is not a simple linear pathway; it is subject to complex regulation at transcriptional, post-transcriptional, and post-translational levels. MicroRNAs and AU-rich element-binding proteins can destabilize mRNAs encoding prostaglandin synthesis enzymes, thereby rapidly altering prostaglandin output. Additionally, prostaglandin transport across membranes, mediated by proteins such as SLCO2A1, influences the availability of prostaglandins for signaling. Dysregulation of prostaglandin biosynthesis is implicated in a wide range of diseases, including chronic inflammation, cancer, and metabolic disorders. Therefore, researchers studying GO:0031392 need robust experimental models to identify and validate the genes and regulatory mechanisms involved.
regulation of prostaglandin biosynthetic process At A Glance
| GO ID | GO:0031392 |
|---|---|
| GO term | regulation of prostaglandin biosynthetic process |
| Ontology | biological_process |
| Synonym | regulation of prostaglandin anabolism; regulation of prostaglandin biosynthesis; regulation of prostaglandin formation; regulation of prostaglandin synthesis |
| Major function | Modulation of the rate, frequency, or extent of prostaglandin biosynthesis |
| Key enzymes | Phospholipase A2, cyclooxygenase-1/2 (PTGS1/PTGS2), prostaglandin E synthases, prostaglandin F synthases, prostaglandin D synthases, prostaglandin I synthase |
| Key transporters | SLCO2A1, ABCC4, MRP4 |
| Regulatory mechanisms | Transcriptional, post-transcriptional (microRNAs, AU-rich elements), post-translational modifications, substrate availability |
| Associated diseases | Inflammation, cancer, cardiovascular disease, metabolic disorders, renal disease |
What Is GO:0031392?
GO:0031392, regulation of prostaglandin biosynthetic process, is defined as any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin. This includes regulation at any step of the biosynthetic cascade, from the release of arachidonic acid to the enzymatic conversion into bioactive prostaglandins, as well as transport and degradation mechanisms that affect local prostaglandin concentrations.
Why Is regulation of prostaglandin biosynthetic process Important in Cell Biology?
Understanding the regulation of prostaglandin biosynthetic process is essential because prostaglandins are ubiquitous lipid mediators that control inflammation, pain, fever, vascular homeostasis, and immune responses. Dysregulated prostaglandin production is a hallmark of many pathological conditions, including arthritis, cancer, and cardiovascular disease. Moreover, prostaglandins play critical roles in metabolic regulation, as shown by studies linking brown fat prostaglandin signaling to systemic insulin sensitivity. Therefore, dissecting the regulatory mechanisms of this pathway can reveal new therapeutic targets and biomarkers.
• Prostaglandins are key drivers of acute and chronic inflammation, making their regulation a therapeutic target for inflammatory diseases.
• Cyclooxygenase (COX) enzymes, especially PTGS2, are overexpressed in many cancers and promote tumor progression.
• Prostaglandin E2 (PGE2) modulates immune cell function and is involved in type 2 inflammation.
• Prostaglandin transport via SLCO2A1 regulates local mediator concentrations and is linked to cardiovascular and renal physiology.
• Renal prostaglandins influence blood flow, salt balance, and kidney function.
• Microglial prostaglandin synthesis is regulated during neuroinflammation and affects neuronal survival.
• Brown adipose tissue prostaglandin signaling regulates systemic insulin sensitivity independently of UCP1.
• Post-transcriptional control by microRNAs and AU-rich elements provides rapid and reversible regulation of prostaglandin synthesis.
• Prostanoids regulate vascular permeability, impacting edema and immune cell infiltration.
• CRISPR-based models enable causal testing of regulatory genes in prostaglandin biosynthesis.
What Happens During regulation of prostaglandin biosynthetic process?
Arachidonic Acid Release and Substrate Supply
In simple terms: The first step is freeing arachidonic acid from cell membranes so it can be converted into prostaglandins.
Prostaglandin biosynthesis begins with the release of arachidonic acid from membrane phospholipids, primarily mediated by phospholipase A2 enzymes. This step is a major regulatory node because the availability of free arachidonic acid directly limits the rate of prostaglandin production. Hormones, growth factors, and inflammatory stimuli can activate phospholipase A2, thereby increasing substrate supply.
Cyclooxygenase-Mediated Conversion
In simple terms: Cyclooxygenase enzymes convert arachidonic acid into intermediate prostaglandin H2.
Cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2) catalyze the conversion of arachidonic acid to prostaglandin G2 and then to prostaglandin H2 (PGH2). PTGS2 is rapidly induced by inflammatory and mitogenic stimuli, while PTGS1 is constitutively expressed in many tissues. The activity of these enzymes is regulated transcriptionally and post-transcriptionally, including by microRNAs and AU-rich element-binding proteins that affect mRNA stability.
Terminal Prostaglandin Synthases
In simple terms: Specific enzymes convert the intermediate PGH2 into different bioactive prostaglandins.
PGH2 is converted by terminal synthases into various prostaglandins, including PGE2, PGF2α, PGD2, PGI2, and TXA2. Each synthase is expressed in a cell-type-specific manner and is subject to regulation, thereby determining the profile of prostaglandins produced. For example, microsomal prostaglandin E synthase-1 (PTGES) is upregulated in inflammation and cancer.
Prostaglandin Transport and Inactivation
In simple terms: Prostaglandins must be transported out of cells to act, and their levels are controlled by uptake and degradation.
Prostaglandins are transported across cell membranes by specific carriers such as SLCO2A1 (prostaglandin transporter) and ABCC4/MRP4. SLCO2A1 mediates uptake and clearance of prostaglandins, thereby regulating local concentrations. The transport process is a key determinant of prostaglandin signaling duration and intensity.
Post-transcriptional and Post-translational Regulation
In simple terms: Cells can quickly adjust prostaglandin production by modifying the stability and activity of synthesis enzymes.
MicroRNAs and AU-rich element-binding proteins can bind to the 3' untranslated regions of mRNAs encoding prostaglandin synthesis enzymes, affecting their stability and translation. Additionally, phosphorylation and other post-translational modifications can modulate enzyme activity. This layer of regulation allows rapid responses to environmental cues.
Key Genes Involved in GO:0031392 regulation of prostaglandin biosynthetic process
The following genes and proteins are central to the regulation of prostaglandin biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G4A | Phospholipase A2, releases arachidonic acid | Rate-limiting substrate supply; target for anti-inflammatory drugs |
| PTGS1 | Cyclooxygenase-1, constitutive prostaglandin synthesis | Housekeeping roles in gastric and renal function |
| PTGS2 | Cyclooxygenase-2, inducible prostaglandin synthesis | Inflammation, cancer, pain; target of NSAIDs like celecoxib |
| PTGES | Microsomal prostaglandin E synthase-1, converts PGH2 to PGE2 | Inflammation, cancer; potential drug target |
| PTGES2 | Microsomal prostaglandin E synthase-2 | PGE2 production in specific tissues |
| PTGES3 | Cytosolic prostaglandin E synthase | PGE2 synthesis; also known as p23 chaperone |
| PTGDS | Prostaglandin D synthase, produces PGD2 | Allergic inflammation, sleep regulation |
| PTGIS | Prostacyclin synthase, produces PGI2 | Vascular homeostasis, cardiovascular disease |
| TBXAS1 | Thromboxane A synthase, produces TXA2 | Platelet aggregation, cardiovascular disease |
| HPGDS | Hematopoietic prostaglandin D synthase | Allergic and inflammatory responses |
| SLCO2A1 | Prostaglandin transporter, mediates uptake | Regulates local prostaglandin levels; mutations cause pachydermoperiostosis |
| ABCC4 | Multidrug resistance protein 4, efflux transporter | Prostaglandin efflux; drug resistance |
| CBR1 | Carbonyl reductase 1, reduces PGE2 to PGF2α | Prostaglandin metabolism |
| AKR1C3 | Aldo-keto reductase, PGH2 to PGF2α | Prostaglandin synthesis in cancer |
| PLA2G4C | Cytosolic phospholipase A2 gamma | Arachidonic acid release in specific tissues |
| PTGER1 | Prostaglandin E receptor 1 | PGE2 signaling; smooth muscle contraction |
| PTGER2 | Prostaglandin E receptor 2 | PGE2 signaling; inflammation, cancer |
| PTGER4 | Prostaglandin E receptor 4 | PGE2 signaling; immune regulation |
How Is regulation of prostaglandin biosynthetic process Regulated?
The regulation of prostaglandin biosynthetic process is achieved through multiple mechanisms. Transcriptional regulation of PTGS2 and terminal synthases by inflammatory mediators such as cytokines and growth factors rapidly increases prostaglandin production. Post-transcriptional regulation by microRNAs and AU-rich element-binding proteins controls mRNA stability and translation of synthesis enzymes. Post-translational modifications, including phosphorylation, modulate enzyme activity. Additionally, prostaglandin transport via SLCO2A1 and ABCC4 regulates the availability of prostaglandins for signaling. Metabolic signals, such as those from brown adipose tissue, can influence systemic prostaglandin levels and insulin sensitivity.
regulation of prostaglandin biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 | Inflammation, cancer | Knockout mice, knock-in humanized models, overexpression cell lines |
| PTGES | Inflammation, cancer | Knockout mice, CRISPR point mutation for catalytic dead |
| SLCO2A1 | Pachydermoperiostosis, cardiovascular | Knockout mice, knock-in patient mutations |
| PTGIS | Cardiovascular disease | Knockout mice, overexpression models |
| TBXAS1 | Thrombosis, cardiovascular | Knockout mice, point mutation for active site |
Inflammation and Inflammatory Diseases
Prostaglandins are major mediators of inflammation, and their overproduction contributes to diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma. PTGS2 is induced by pro-inflammatory stimuli, and its product PGE2 promotes vasodilation, edema, and pain. Targeting prostaglandin biosynthesis with NSAIDs or COX-2 selective inhibitors is a mainstay of anti-inflammatory therapy.
Cancer
Dysregulated prostaglandin biosynthesis is common in many cancers. PTGS2 is overexpressed in colorectal, breast, and lung cancers, where PGE2 promotes cell proliferation, angiogenesis, and immune evasion. MicroRNA-mediated regulation of prostaglandin synthesis genes can influence tumor progression. Therefore, components of this pathway are potential targets for cancer therapy.
Cardiovascular and Renal Disease
Prostaglandins regulate vascular tone, platelet aggregation, and renal function. An imbalance between prostacyclin (PGI2) and thromboxane A2 (TXA2) contributes to thrombosis and hypertension. Renal prostaglandins modulate blood flow and salt excretion, and their dysregulation is implicated in kidney disease.
Metabolic Disorders
Prostaglandin signaling in brown adipose tissue regulates systemic insulin sensitivity, as shown by studies in mice. This inter-organ signaling axis operates independently of UCP1 and highlights the role of prostaglandins in metabolic homeostasis. Dysregulation of this pathway may contribute to obesity and type 2 diabetes.
From regulation of prostaglandin biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTGS2 reduce inflammation? | PTGS2 knockout mice or cell lines |
| Does a specific point mutation in PTGES abolish PGE2 synthesis? | CRISPR point mutation knock-in cell lines |
| Does overexpression of SLCO2A1 alter prostaglandin uptake? | Overexpression cell lines or transgenic mice |
| Does a tagged PTGS2 reveal its subcellular localization? | Knock-in of fluorescent or epitope tag |
| Does knockout of PLA2G4A affect arachidonic acid release? | PLA2G4A knockout cells |
| Does a regulatory SNP in PTGS2 affect transcription? | Knock-in of SNP using CRISPR |
How to Study the regulation of prostaglandin biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of synthesis enzymes and transporters | Transcriptional regulation studies |
| Western blot | Protein expression and post-translational modifications | Validation of enzyme levels |
| LC-MS/MS lipidomics | Prostaglandin species and quantities | Pathway output measurement |
| COX activity assay | Enzymatic conversion of arachidonic acid | Functional validation of PTGS1/2 |
| CRISPR knockout screen | Genes affecting prostaglandin production | Discovery of novel regulators |
| Immunofluorescence | Subcellular localization of enzymes | Organelle-specific synthesis |
| Prostaglandin transport assay | Uptake/efflux of prostaglandins | SLCO2A1 and ABCC4 function |
Gene Expression Analysis
Quantitative RT-PCR, RNA-seq, and microarray can measure mRNA levels of prostaglandin synthesis enzymes and transporters. These methods are used to assess transcriptional regulation in response to stimuli.
Protein and Enzyme Activity Assays
Western blotting, immunoprecipitation, and enzyme activity assays (e.g., COX activity) measure protein levels and catalytic activity of prostaglandin synthesis enzymes. These methods help determine post-translational regulation.
Lipid Mediator Profiling
Mass spectrometry-based lipidomics quantifies prostaglandin levels in cells, tissues, and biofluids. This provides direct readout of pathway output and is essential for validating regulatory mechanisms.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of prostaglandin biosynthesis. These screens are powerful for discovering genes that modulate pathway activity.
How CRISPR Can Be Used to Study GO:0031392 regulation of prostaglandin biosynthetic process
Knockout
CRISPR knockout of genes such as PTGS2, PTGES, or SLCO2A1 can abolish or reduce prostaglandin biosynthesis, providing causal evidence for their roles. Knockout cell lines and mice are widely used to study inflammation and cancer.
Point Mutation
CRISPR point mutation knock-in can introduce catalytic-dead mutations or disease-associated SNPs into genes like PTGS2 or PTGES. These models help dissect the contribution of specific enzymatic activities or regulatory elements.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes into endogenous loci allows real-time tracking of protein expression and localization. This is useful for studying dynamic regulation of prostaglandin synthesis enzymes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase expression of prostaglandin synthesis genes, enabling gain-of-function studies. Overexpression models are valuable for testing sufficiency of a gene in driving prostaglandin production.
How EDITGENE Supports regulation of prostaglandin biosynthetic process Research
Researchers studying regulation of prostaglandin biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation or is merely correlated with changes in prostaglandin levels. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for regulation of prostaglandin biosynthetic process research.
Frequently Asked Questions About regulation of prostaglandin biosynthetic process
What is GO:0031392?
GO:0031392 is the Gene Ontology term for regulation of prostaglandin biosynthetic process, defined as any process that modulates the frequency, rate or extent of prostaglandin biosynthesis.
What genes are involved in regulation of prostaglandin biosynthetic process?
Key genes include PLA2G4A, PTGS1, PTGS2, PTGES, PTGDS, PTGIS, TBXAS1, SLCO2A1, and ABCC4, among others.
How is prostaglandin biosynthesis regulated?
It is regulated at multiple levels: substrate release by phospholipase A2, transcriptional induction of COX-2, post-transcriptional control by microRNAs and AU-rich elements, and transport-mediated clearance.
What diseases are associated with dysregulated prostaglandin biosynthesis?
Dysregulation is linked to inflammation, cancer, cardiovascular disease, renal disease, and metabolic disorders.
What is the role of PTGS2 in prostaglandin biosynthesis?
PTGS2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandin H2, a precursor for various prostaglandins, and is a key target of anti-inflammatory drugs.
How do microRNAs regulate prostaglandin synthesis?
MicroRNAs can bind to AU-rich elements in the 3' UTR of mRNAs encoding prostaglandin synthesis enzymes, leading to mRNA degradation or translational repression.
What is the function of SLCO2A1 in prostaglandin regulation?
SLCO2A1 is a prostaglandin transporter that mediates cellular uptake and clearance, thereby controlling local prostaglandin concentrations.
Can CRISPR be used to study prostaglandin biosynthesis?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes in prostaglandin biosynthesis.
What experimental models are available for studying prostaglandin regulation?
Models include knockout mice, CRISPR-edited cell lines, overexpression systems, and lipidomics assays to measure prostaglandin output.
Why is prostaglandin biosynthesis important in cancer?
Prostaglandins, especially PGE2, promote tumor cell proliferation, angiogenesis, and immune evasion, making the pathway a target for cancer therapy.
Conclusion
The regulation of prostaglandin biosynthetic process (GO:0031392) is a complex and highly controlled pathway essential for inflammation, vascular biology, and metabolic homeostasis. Dysregulation of this pathway contributes to numerous diseases, including cancer, cardiovascular disease, and metabolic disorders. Understanding the molecular mechanisms and identifying the genes involved requires robust experimental models. CRISPR-based approaches, such as knockout, point mutation, knock-in, and overexpression, provide powerful tools to dissect causality. EDITGENE offers comprehensive services to support such research, from custom cell line generation to CRISPR library screening and bioinformatics analysis.
References
- 1. Xiao L et al.. 2024. m(6)A mRNA methylation in brown fat regulates systemic insulin sensitivity via an inter-organ prostaglandin signaling axis independent of UCP1.. Cell Metab 36(10):2207-2227.e9 PMID: 39255799
- 2. Oyesola OO et al.. 2021. Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions.. Eur J Immunol 51(10):2399-2416 PMID: 34396535
- 3. Schuster VL. 2002. Prostaglandin transport.. Prostaglandins Other Lipid Mediat 68-69:633-47 PMID: 12432949
- 4. Moore AE et al.. 2011. MicroRNA and AU-rich element regulation of prostaglandin synthesis.. Cancer Metastasis Rev 30(3-4):419-35 PMID: 22005950
- 5. Xia Z et al.. 2025. Structure and transport mechanism of the human prostaglandin transporter SLCO2A1.. Nat Commun 16(1):8124 PMID: 40885756
- 6. Horikami D et al.. 2020. [Prostanoids regulate vascular permeability].. Nihon Yakurigaku Zasshi 155(6):395-400 PMID: 33132257
- 7. Makhoul RG et al.. 1986. Renal prostaglandins.. J Surg Res 40(2):181-92 PMID: 3511324
- 8. Levi G et al.. 1998. Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions.. Biochimie 80(11):899-904 PMID: 9893949
